Brief: Herantis Pharma H2 Loss For The Period Widens To EUR 4.7 Mln

Herantis Pharma Oyj

27/02/2020 15:03

Feb 27 (Reuters) - Herantis Pharma Oyj  HRTIS.HE :
    * GUIDANCE FOR 2020: CO  DOES NOT EXPECT MATERIAL REVENUES
IN 2020
    * MAIN OBJECTIVES FOR 2020 ARE TO PRESENT INITIAL RESULTS OF
PHASE
1-2 CLINICAL STUDY OF CDNF IN Q1, AND TWELVE-MONTH FOLLOW-UP
RESULTS IN Q3
    * H2 LOSS FOR THE PERIOD EUR 4.7 MILLION VERSUS LOSS EUR 2.4
MILLION YEAR AGO

Source text for Eikon:  ID:nWkrXN1tn 
Further company coverage:  HRTIS.HE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))